Advicenne was founded in 2007 by Luc-André Granier and Caroline Roussel-Maupetit with the objective of developing and commercialising orphan drugs suitable for patients of all ages, and especially children, in the fields of neurology and nephrology.
Luc-André Granier, MD, PhD
Luc-André Granier co-founded Advicenne in 2007 and was the company’s CEO, Medical Director until 2020. He is an expert in the pharmaceutical development of innovative therapeutic products in the field of the central nervous system, and brings to Advicenne more than twenty-five years of experience in the pharmaceutical and biotech industries.
In his work with companies such as Eli Lilly and Company, Synt:em and Forenap, Luc-André has overseen a number of clinical trials and led numerous programs for the development of drugs to treat neurological disorders, primarily in the areas of pain, migraine, neuro-degenerative diseases and psychiatric disorders. He was responsible for the successful proof of concept study for the “blockbuster” duloxetine (Cymbalta, Xeristar, Yentreve), approved by the FDA in 2004.
Luc-André holds Doctor of Medicine and Doctor of Science degrees from Louis Pasteur University (Strasbourg, France), where he specialized in biochemistry, and molecular and cellular biology. He is a member of several national and international scientific societies in the fields of pain, epilepsy and renal diseases, including the International League Against Epilepsy (ILAE), American Society of Nephrology (ASN) and the International Pediatric Nephrology Association (IPNA).
Caroline Roussel-Maupetit co-founded Advicenne and has served as the company’s Director of Operations since its inception in 2007, and as its General Manager until 2020.
Having participated in the creation of three French biotechnology companies, Caroline brings to her work at Advicenne an extensive background in the pharmaceutical development of innovative therapeutic products, in particular in its technical and regulatory aspects, and in the area of subcontracting management.
In 1995, Caroline co-founded Syn:tem, a French biotech company focused on the treatment of oncology, pain management and diseases of the central nervous system, serving as the company’s Chief Operating Officer until its acquisition by CLL Pharma SA in 2005. Prior to founding Synt:em, she served as Marketing Manager for Protein Performance, a company specializing in the development of recombinant proteins.
Caroline holds degrees in industrial biological engineering from the University of Technology of Compiègne (UTC) and in management from IEDE Montpellier.
Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.
© 2020 Advicenne